LETERMOVIR FOR CYTOMEGALOVIRUS PREVENTION IN RELAPSED/REFRACTORY ACUTE LEUKEMIA AND LYMPHOMA RECEIVING SEQUENTIAL CD7 CAR-T CELL THERAPY BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - Mar 14, 2026 - Abstract #A183; Pres time: Mar 23, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "The treatment dose was letermovir 480 mg qd, reduced to 240 mg qd for patients concurrently taking cyclosporine...One patient (11.1%) experienced a breakthrough CMV infection on day 14 post-transplantation, with an initial CMV DNA load of 914 copies/mL; the infection resolved after 2 days of adjunctive ganciclovir therapy, with subsequent CMV DNA conversion to negative... In a real-world setting, letermovir demonstrated significant efficacy in preventing CMV infection in patients with acute leukemia and lymphoma undergoing sequential CD7 CAR-T cell therapy bridging allo-HSCT. The high risk of CMV reactivation post-CAR-T therapy has been confirmed in multiple studies. The CMV infection rate observed in this study is significantly lower than previously reported rates for CD7 CAR-T bridging transplantation."
CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD7
|
|
Linwei Shi1; Xiaoli Zhao1; Aiming Pang1
|